Patent · US Active

CD70 combination therapy

US12180293B2 · kind B2 · utility

0Cited by

36References

18Claims

0Family size

Assignee

argenx BV · BE

Inventors

Luc Van Rompaey · Mechelen, BE
Mahan Moshir · Wondelgem, BE
Tim Delahaye · Zwijnaarde, BE
Piotr Zabrocki · Zwijnaarde, BE

Key dates

Filing date	Nov 10, 2022
Grant date	Dec 31, 2024
Priority date	—
Expiry date	Nov 10, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to combination therapies for the treatment of malignancy, particularly myeloid malignancy such as acute myeloid leukemia (AML). The combination therapies may include an antibody molecule that binds to CD70 and at least one antibody molecule that binds to a leukemic stem cell target. Preferred leukemic stem cell targets are TIM-3, IL1R3/1L1RAP and CD47.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.